Allison Inserro

Allison is Associate Editorial Director for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®. She joined AJMC® in 2017. She produces and oversees written, video, and podcast content across several disease states and issues surrounding value-based care and health policy.

She has an MPA from New York University. You can connect with Allison on LinkedIn.

Articles by Allison Inserro

How can the health industry ensure that cutting-edge gene therapies and other curative treatments get to the patients that need them, without leaving payers financially exposed? Representatives of payers and biotechnology companies discussed some of the novel discussions that are taking place as they work through issues of expense and access during “Paying for Cures: Ensuring patient access and system sustainability," a 1-day event in Washington, DC.

HHS released 2 long-awaited rules meant to transform how health records and medical claims are delivered and communicated, with one aimed at aggregating electronic health records and claims information into an interoperable mobile format that patients could call up on their devices and another that would require that access to electronic health information come at no cost to the patient and end information blocking.

A new report from the Commonwealth Fund looking at healthcare coverage said the uninsured rate is basically unchanged from before President Trump took office, but that more people, primarily those who have coverage through work, are underinsured. By late fall of 2018, 12.4% of adults were uninsured, down from a high of 20% before the Affordable Care Act became law.

Top Congressional Democrats sent a request to the Government Accountability Office (GAO) asking it to determine if guidance issued by CMS in October 2018 in relation to the Section 1332 waivers states can pursue is subject to legislative oversight. Meanwhile, a report said none of the 8 states that have approval to create a work requirement for their Medicaid expansion pool of beneficiaries have plans to track whether enrollees find jobs or improve their health.

HHS Secretary Alex Azar proposed Thursday to end drug rebates in Medicare Part D and in Medicaid managed care plans and treat them as kickbacks, in a move that could have implications for private plans as well. The rule was announced in the same week as hearings on Capitol Hill about drug pricing, especially the rising cost of insulin.

Researchers used a blood test to look for biomarkers indicative of Alzheimer disease in a group of people with a genetic mutation for a familial form of the disease, and they said the test can predict differences about 16 years before affected patients are expected to begin showing symptoms. The hope is that a blood test could one day be used to identify brain disease for not only Alzheimer disease but also other neurodegenerative conditions, such as multiple sclerosis, traumatic brain injury, or stroke.



Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo